TCR-T cell therapy for solid tumors: challenges and emerging solutions
With the use of T cell receptor T cells (TCR-T cells) and chimeric antigen receptor T cells (CAR-T cells), T-cell immunotherapy for cancer has advanced significantly in recent years. CAR-T cell therapy has demonstrated extraordinary success when used to treat hematologic malignancies. Nevertheless,...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1493346/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850072481800388608 |
|---|---|
| author | Wanjun He Wanjun He Kai Cui Kai Cui Muhammad Asad Farooq Na Huang Na Huang Songshan Zhu Songshan Zhu Dan Jiang Dan Jiang Xiqian Zhang Xiqian Zhang Xiqian Zhang Jian Chen Yinxia Liu Guangxian Xu Guangxian Xu |
| author_facet | Wanjun He Wanjun He Kai Cui Kai Cui Muhammad Asad Farooq Na Huang Na Huang Songshan Zhu Songshan Zhu Dan Jiang Dan Jiang Xiqian Zhang Xiqian Zhang Xiqian Zhang Jian Chen Yinxia Liu Guangxian Xu Guangxian Xu |
| author_sort | Wanjun He |
| collection | DOAJ |
| description | With the use of T cell receptor T cells (TCR-T cells) and chimeric antigen receptor T cells (CAR-T cells), T-cell immunotherapy for cancer has advanced significantly in recent years. CAR-T cell therapy has demonstrated extraordinary success when used to treat hematologic malignancies. Nevertheless, there are several barriers that prevent this achievement from being applied to solid tumors, such as challenges with tumor targeting and inadequate transit and adaption of genetically modified T-cells, especially in unfavorable tumor microenvironments The deficiencies of CAR-T cell therapy in the treatment of solid tumors are compensated for by TCR-T cells, which have a stronger homing ability to initiate intracellular commands, 90% of the proteins can be used as developmental targets, and they can recognize target antigens more broadly. As a result, TCR-T cells may be more effective in treating solid tumors. In this review, we discussed the structure of TCR-T and have outlined the drawbacks of TCR-T in cancer therapy, and suggested potential remedies. This review is crucial in understanding the current state and future potential of TCR-T cell therapy. We emphasize how important it is to use combinatorial approaches, combining new combinations of various emerging strategies with over-the-counter therapies designed for TCR-T, to increase the anti-tumor efficacy of TCR-T inside the TME and maximize treatment safety, especially when it comes to solid tumor immunotherapies. |
| format | Article |
| id | doaj-art-0be99d2b2f1d4fe8aa2a1e2ab357dcd4 |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-0be99d2b2f1d4fe8aa2a1e2ab357dcd42025-08-20T02:47:04ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.14933461493346TCR-T cell therapy for solid tumors: challenges and emerging solutionsWanjun He0Wanjun He1Kai Cui2Kai Cui3Muhammad Asad Farooq4Na Huang5Na Huang6Songshan Zhu7Songshan Zhu8Dan Jiang9Dan Jiang10Xiqian Zhang11Xiqian Zhang12Xiqian Zhang13Jian Chen14Yinxia Liu15Guangxian Xu16Guangxian Xu17Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Molecular Immunology and Cell Therapy, Guangdong Medical University, Dongguan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Molecular Immunology and Cell Therapy, Guangdong Medical University, Dongguan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Molecular Immunology and Cell Therapy, Guangdong Medical University, Dongguan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Molecular Immunology and Cell Therapy, Guangdong Medical University, Dongguan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Molecular Immunology and Cell Therapy, Guangdong Medical University, Dongguan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Molecular Immunology and Cell Therapy, Guangdong Medical University, Dongguan, ChinaYinchuan Guolong Orthopedic Hospital, Yinchuan, ChinaYinchuan Guolong Orthopedic Hospital, Yinchuan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan, ChinaDongguan Key Laboratory of Molecular Immunology and Cell Therapy, Guangdong Medical University, Dongguan, ChinaWith the use of T cell receptor T cells (TCR-T cells) and chimeric antigen receptor T cells (CAR-T cells), T-cell immunotherapy for cancer has advanced significantly in recent years. CAR-T cell therapy has demonstrated extraordinary success when used to treat hematologic malignancies. Nevertheless, there are several barriers that prevent this achievement from being applied to solid tumors, such as challenges with tumor targeting and inadequate transit and adaption of genetically modified T-cells, especially in unfavorable tumor microenvironments The deficiencies of CAR-T cell therapy in the treatment of solid tumors are compensated for by TCR-T cells, which have a stronger homing ability to initiate intracellular commands, 90% of the proteins can be used as developmental targets, and they can recognize target antigens more broadly. As a result, TCR-T cells may be more effective in treating solid tumors. In this review, we discussed the structure of TCR-T and have outlined the drawbacks of TCR-T in cancer therapy, and suggested potential remedies. This review is crucial in understanding the current state and future potential of TCR-T cell therapy. We emphasize how important it is to use combinatorial approaches, combining new combinations of various emerging strategies with over-the-counter therapies designed for TCR-T, to increase the anti-tumor efficacy of TCR-T inside the TME and maximize treatment safety, especially when it comes to solid tumor immunotherapies.https://www.frontiersin.org/articles/10.3389/fphar.2025.1493346/fulladoptive cell therapyimmunotherapysolid tumorTCRTCR-T cell |
| spellingShingle | Wanjun He Wanjun He Kai Cui Kai Cui Muhammad Asad Farooq Na Huang Na Huang Songshan Zhu Songshan Zhu Dan Jiang Dan Jiang Xiqian Zhang Xiqian Zhang Xiqian Zhang Jian Chen Yinxia Liu Guangxian Xu Guangxian Xu TCR-T cell therapy for solid tumors: challenges and emerging solutions Frontiers in Pharmacology adoptive cell therapy immunotherapy solid tumor TCR TCR-T cell |
| title | TCR-T cell therapy for solid tumors: challenges and emerging solutions |
| title_full | TCR-T cell therapy for solid tumors: challenges and emerging solutions |
| title_fullStr | TCR-T cell therapy for solid tumors: challenges and emerging solutions |
| title_full_unstemmed | TCR-T cell therapy for solid tumors: challenges and emerging solutions |
| title_short | TCR-T cell therapy for solid tumors: challenges and emerging solutions |
| title_sort | tcr t cell therapy for solid tumors challenges and emerging solutions |
| topic | adoptive cell therapy immunotherapy solid tumor TCR TCR-T cell |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1493346/full |
| work_keys_str_mv | AT wanjunhe tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT wanjunhe tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT kaicui tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT kaicui tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT muhammadasadfarooq tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT nahuang tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT nahuang tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT songshanzhu tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT songshanzhu tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT danjiang tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT danjiang tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT xiqianzhang tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT xiqianzhang tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT xiqianzhang tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT jianchen tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT yinxialiu tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT guangxianxu tcrtcelltherapyforsolidtumorschallengesandemergingsolutions AT guangxianxu tcrtcelltherapyforsolidtumorschallengesandemergingsolutions |